replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.
![Replimune logo](/files/LOGO/1737953-REPL.png)
Company profile
Ticker
REPL
Exchange
Website
CEO
Robert Coffin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Replimune, Inc. • Replimune Limited • Replimune Securities Corporation • Replimune (Ireland) Limited ...
REPL stock data
Latest filings (excl ownership)
8-K
Replimune Announces $100 Million Private Placement Financing
13 Jun 24
8-K
Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024
6 Jun 24
8-K
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
3 Jun 24
S-8
Registration of securities for employees
16 May 24
POS AM
Prospectus update (post-effective amendment)
16 May 24
10-K
2024 FY
Annual report
16 May 24
POSASR
Automatic shelf registration (post-effective amendment)
16 May 24
8-K
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
16 May 24
8-K
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
26 Mar 24
10-Q
2024 Q3
Quarterly report
8 Feb 24
Latest ownership filings
4
Konstantinos Xynos
10 Jun 24
144
Notice of proposed sale of securities
7 Jun 24
144
Notice of proposed sale of securities
23 May 24
4
Christopher Sarchi
20 May 24
4
Andrew Schwendenman
20 May 24
4
Colin Love
20 May 24
4
Philip Astley-Sparke
20 May 24
4
Robert Coffin
20 May 24
4
Sushil Patel
20 May 24
4
Konstantinos Xynos
20 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 76.16 mm | 76.16 mm | 76.16 mm | 76.16 mm | 76.16 mm | 76.16 mm |
Cash burn (monthly) | 7.72 mm | 6.01 mm | 19.59 mm | 19.56 mm | 15.39 mm | 15.46 mm |
Cash used (since last report) | 20.72 mm | 16.12 mm | 52.58 mm | 52.52 mm | 41.31 mm | 41.49 mm |
Cash remaining | 55.44 mm | 60.03 mm | 23.58 mm | 23.64 mm | 34.85 mm | 34.67 mm |
Runway (months of cash) | 7.2 | 10.0 | 1.2 | 1.2 | 2.3 | 2.2 |
Institutional ownership, Q1 2024
40.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 48 |
Opened positions | 16 |
Closed positions | 66 |
Increased positions | 11 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 54.22 bn |
Total shares | 24.73 mm |
Total puts | 74.50 k |
Total calls | 12.90 k |
Total put/call ratio | 5.8 |
Largest owners | Shares | Value |
---|---|---|
T. Rowe Price | 6.55 mm | $0.00 |
Forbion Capital Fund III Cooperatief U.A. | 5.19 mm | $0.00 |
FCPM Iii Services B.V. | 4.87 mm | $39.76 bn |
Omega Fund IV | 3.61 mm | $0.00 |
Atlas Venture Fund X | 1.50 mm | $29.33 mm |
Foresite Capital Fund III | 1.23 mm | $18.64 mm |
Emerald Advisers | 492.22 k | $4.02 bn |
TD Asset Management | 238.85 k | $1.95 bn |
BK Bank Of New York Mellon | 162.76 k | $1.33 bn |
Emerald Mutual Fund Advisers Trust | 132.41 k | $1.08 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Jun 24 | Konstantinos Xynos | Common Stock | Sell | Dispose S | No | Yes | 7.5 | 15,881 | 119.11 k | 117,131 |
16 May 24 | Konstantinos Xynos | Common Stock | Sell | Dispose S | No | No | 6.47 | 6,367 | 41.19 k | 133,012 |
16 May 24 | Sushil Patel | Common Stock | Sell | Dispose S | No | No | 6.47 | 20,194 | 130.66 k | 212,014 |
16 May 24 | Robert Coffin | Common Stock | Sell | Dispose S | No | No | 6.47 | 11,464 | 74.17 k | 1,821,872 |
16 May 24 | Philip Astley-Sparke | Common Stock | Sell | Dispose S | No | No | 6.47 | 37,928 | 245.39 k | 1,487,350 |
News
Barclays Maintains Overweight on Replimune Group, Raises Price Target to $17
7 Jun 24
Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday's Pre-Market Session
7 Jun 24
HC Wainwright & Co. Maintains Buy on Replimune Group, Raises Price Target to $17
7 Jun 24
S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat
6 Jun 24
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
6 Jun 24
Press releases
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
7 Jun 24
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
23 May 24
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
16 May 24
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
7 Apr 24
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Apr 24